CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00539695
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:56.326573+00:00
Published At: 2014-07-04T00:00:00+00:00
Record Updated At: 2018-05-04
Results Posted At: 2014-07-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Lymphoblastic Leukemia", "ALL", "Acute Myelogenous Leukemia", "AML", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Disorder", "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Non-malignant Diseases Requiring Allogeneic HSCT"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-05-04"
protocolSection.identificationModule.nctId: "NCT00539695"
protocolSection.identificationModule.officialTitle: "Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2014-07-04"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.